Franklin Berger
Managing Director for Equity Research & Senior Biotechnology Analyst @ J.P. Morgan Securities Inc.
New York, United States
Franklin Berger is a seed investor at J.P. Morgan Securities Inc. in New York focused on Health Care and Therapeutics. Franklin Berger has served as a member of our board of directors since September 2010. Franklin Berger is a consultant to biotechnology industry participants, including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies, providing business development, strategicadvisory, financing, partnering, and royalty acquisition advice. Franklin Berger is also a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. Franklin Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from 2007 through June 2008.From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. In this position, he initiated coverage of 26 biotechnology companies and was responsible for technical, scientific and clinical due diligence as well as company selection.Franklin began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst. Franklin currently serves on the board of directors of three biotechnology companies: Five Prime Therapeutics, Inc., Immune Design Corp. and Bellus Health, Inc. Previous public company board service included 11 years with Seattle Genetics, Inc., 7 years with VaxGen, Inc. and Aurinia Pharmaceuticals Inc. (previously Isotechnika Pharma Inc.), based in Canada. He also serves or has served on biotech company boards of directors including iTherX Pharma, Inc., Caprion Proteomics Inc. and ViroChem Pharma, Inc. (purchased by Vertex Pharmaceuticals, Inc. for $400 million in 2009). Franklin has led multiple M&A analyses resulting in greater than $1 billion in transaction value.. Franklin received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Franklin Berger invests in
Stages Franklin Berger invests in
Countries Franklin Berger invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (50%)
- Therapeutics 4 (50%)
- Biotechnology 4 (50%)
- Medical 2 (25%)
- Wellness 1 (13%)
Stage
- Seed 2 (25%)
- Series A 2 (25%)
- Series B 2 (25%)
- Series C 1 (13%)
- Funding Round 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | ||
| Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $48M / Series A / Jul 20, 2022 | ||
| MindRhythm is a medical device company focused on applying novel biometrics to stroke and concussion patients to improve diagnosis, triage and management. Their proprietary monitoring devices and communication platform provide novel and real-time visibility to life-threatening situations prehospital and in the operating room, allowing clinicians tointervene earlier and with better precision to prevent brain damage. | $5M / Seed / Aug 24, 2021 | ||
| Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $12.8M / Seed / Jan 28, 2021 | ||
| Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, andenhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing.It was founded in 2012 and is headquartered in South San Francisco, California. | $62M / Series C / Sep 24, 2019 | ||
| Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $25M / Series B / Feb 01, 2019 | ||
| Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $6.1M / Series A / Feb 08, 2017 | ||
| FivePrime is discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant proteins in the human body to find the best protein for treatment of a given clinical indication. FivePrime’s ProScreen Engine enables the rapid production and screening of all therapeuticallyrelevant proteins in medically-focused assays at the highest quality standards in the industry. This powerful approach is the polar opposite of the industry’s traditional “one protein at a time”. The ProScreen Engine comprises the definitive protein collection and screening process for biologics discovery and is unprecedented in its efficiency, quality, and scale. In addition to DBL Investors, investors include Domain Associates, Versant Ventures, Kleiner Perkins Caufield and Byers, Texas Pacific Group, HealthCap, and Advanced Technology Ventures. | $45M / Feb 08, 2005 |
Co-Investors
J.P. Morgan is a global industry leader with more than $13.7 trillion in assets under custody and $5.1 trillion in assets under administration. They provide innovative custody, fund accounting and administration and securities services to the world's largest institutional investors, alternative asset managers and debt and equity issuers.They leverage scale and capabilities in more than 90 markets to help clients optimize efficiency, mitigate risk and enhance revenue through a broad range of investor services as well as securities clearance, collateral management and alternative investment services.As a strategic partner with a long-standing commitment and proven experience, J.P. Morgan takes a consultative approach to working with clients to assess and address their individual needs. J.P. Morgan is a leader in asset management, investment banking, private banking, treasury and securities services, and commercial banking. Today, the firm serves one of the largest client franchises in the world, including corporations, institutional investors, hedge funds, governments and affluent individuals in more than 100 countries.J.P. Morgan's core businesses include:Asset Management Investment BankPrivate BankingSecurities ServicesTreasury ServicesCommercial Banking
J.P. Morgan Securities Inc. Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Douglas Anmuth
Managing Director, Internet Analyst
|
|||
|
Efstathios N Karanikolaidis
Managing Director
|
|||
Fernando Okumura
Team Member
|
|||
|
Imran Khan
Managing Director
|
|||
Imran Khan
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Franklin Berger invest in?
Franklin Berger invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Franklin Berger?
Public channels for Franklin Berger include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Franklin Berger last invest?
The most recent investment recorded for Franklin Berger closed in Feb 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
